# OnCo record fedratinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fedratinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fedratinib" ;
  schema:name "Fedratinib"@en ;
  schema:description "A second JAK inhibitor for myelofibrosis that works after ruxolitinib fails; it carries a boxed warning for a rare brain toxicity (Wernicke encephalopathy) so thiamine is checked."@en ;
  schema:url <https://onco.cc/drugs/fedratinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Fedratinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q7670147> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=fedratinib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule JAK2/FLT3 inhibitor" ;
  schema:alternateName "Inrebic" ;
  onco:approval "US 2019: Intermediate-2/high-risk primary or secondary myelofibrosis", "EU 2021: Myelofibrosis, JAK-inhibitor-naive or after ruxolitinib" ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/>, <https://onco.cc/cancers/primary-myelofibrosis/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/flt3/>, <https://onco.cc/targets/brd4/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct04817007/> .